In a recent review entitled : Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy, Junjie Wu and David Waxman from the Department of Biology, Division of Cell and Molecular Biology, Boston University, Boston USA review the data about metronomic chemotherapy (MC) and its impact on immunity

Indeed, some anti-cancer chemotherapeutic drugs, such as doxorubicin, mitoxantrone, and cyclophosphamide, can kill tumor cells by an immunogenic cell death pathway. In turn it activates both innate and adaptive anti-tumor immune responses More specifically, dose and schedule of administration of MC can impact on anti-tumor immune responses. Strategy for effective immunogenic chemotherapy that rely on a modified metronomic schedule for drug delivery are proposed: medium-dose intermittent chemotherapy (MEDIC). Striking responses have been seen in preclinical cancer models using MEDIC, where an immunogenic cancer chemotherapeutic agent is administered intermittently and at an intermediate dose, designed to impart strong and repeated cytotoxic damage to tumors, and on a schedule compatible with activation of a sustained anti-tumor immune response, thereby maximizing anti-cancer activity. Of MEDIC can be then used for developing strategies for combination chemo-immunotherapy are explored.

The full text is available in the Cancer Letters Website here